Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) saw a significant decline in short interest in January. As of January 31st, there was short interest totalling 1,100,000 shares, a decline of 6.0% from the January 15th total of 1,170,000 shares. Currently, 5.0% of the shares of the company are short sold. Based on an average daily volume of 60,300 shares, the short-interest ratio is presently 18.2 days.

Institutional Trading of Acrivon Therapeutics

A number of hedge funds have recently modified their holdings of ACRV. China Universal Asset Management Co. Ltd. acquired a new position in shares of Acrivon Therapeutics in the fourth quarter worth about $40,000. Corton Capital Inc. purchased a new stake in Acrivon Therapeutics during the 4th quarter valued at about $73,000. American Century Companies Inc. raised its holdings in Acrivon Therapeutics by 14.2% in the 4th quarter. American Century Companies Inc. now owns 17,588 shares of the company’s stock valued at $106,000 after acquiring an additional 2,186 shares during the last quarter. Barclays PLC raised its stake in Acrivon Therapeutics by 51.2% during the third quarter. Barclays PLC now owns 33,306 shares of the company’s stock worth $233,000 after purchasing an additional 11,273 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of Acrivon Therapeutics by 548.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock valued at $238,000 after buying an additional 28,748 shares during the period. Hedge funds and other institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Trading Up 1.1 %

Shares of NASDAQ:ACRV opened at $5.42 on Tuesday. The company has a market cap of $168.78 million, a PE ratio of -2.01 and a beta of 0.77. The company’s 50 day moving average is $6.03 and its 200 day moving average is $7.15. Acrivon Therapeutics has a twelve month low of $3.34 and a twelve month high of $11.90.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ACRV shares. Cantor Fitzgerald started coverage on shares of Acrivon Therapeutics in a research report on Friday, January 31st. They issued an “overweight” rating for the company. HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of Acrivon Therapeutics in a research note on Thursday, November 14th. KeyCorp began coverage on shares of Acrivon Therapeutics in a research note on Friday, January 31st. They set an “overweight” rating for the company. Finally, BMO Capital Markets decreased their price target on shares of Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating for the company in a research report on Thursday, November 14th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Acrivon Therapeutics presently has a consensus rating of “Buy” and an average price target of $23.67.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.